The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Open accessAbstract
Activation of the tyrosine kinase of the c-src gene product, pp60c-src, has been shown to occur in nearly every primary colorectal carcinoma, and is found as early as in polyps of high malignant potential. However, no studies have addressed potential pp60c-src changes which occur during progression. To examine this question, we have studied kinase activity and protein levels in 7 colonic polyps, 19 primary lesions, and 19 liver metastases relative to normal colonic mucosa. Significant increases in tyrosine kinase activity were seen as early as in colonic polyps of high malignant potential. Further increases were observed in activity and level in primary tumors. However, the greatest increases in activity and protein levels were observed in liver metastases. Additionally, six metastatic lesions were obtained in which synchronous primary tumor was resected. In each of these liver metastases, pp60c-src activity and level were significantly increased relative to the corresponding primary tumor, as well as to normal colonic mucosa. Our results demonstrate that progression of colon primary tumors to liver metastases correlates with increased pp60c-src kinase activity and protein level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the SRC activation signature score was significantly associated with metastasis and primary tumor stage I-IV progression (Fig. 2g,h), in agreement with previous studies in CRC [37–40].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Talamonti et al reported increased activity and expression of SFKs in progressive stages of human colorectal cancer, suggesting that colon cancer progression may be dependent on increased SFK protein level and subsequent activity (Talamonti et al., 1993).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Talamonti et al., 1993
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Higher expression and activity of SRC has been documented in primary colon tumors compared with benign polyps or non-transformed colonic mucosa, and increased activity is observed in progressive stages of CRC [23–26].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [25]
In the citing paper
“However, c-Src seems to experience a robust increase in expression and activity in CRC liver metastases compared with metastases derived from other tumors types [11, 12]”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [12]
In the citing paper
“C-src, though, seems to have a robust increase regarding expression and activity in CRC liver metastases compared to those derived from other tumors types.3,11,13”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
In the citing paper
“In CRC cell lines and primary tumors, both c-src kinase activity and protein expression levels have been found elevated compared either to normal colonic mucosal cells and fibroblasts or normal adjacent tissue, respectively.3,10,11”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
In the citing paper
“Increased specific activity and expression levels have been detected in colonic polyps of high malignant potential and severe dysplasia.11,12”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,311
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Identification and characterization of the familial adenomatous polyposis coli gene
Groden, J. L., Thliveris, A. T., Samowitz, W. S., Carlson, M. L., Gelbert, L. M., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L. N., Robertson, M. A., et al. (1991) · Cell · doi:10.1016/0092-8674(81)90021-0 · Cited by 2,794
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler‐Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,701
Identification of FAP Locus Genes from Chromosome 5q21
Kinzler, K. W., Nilbert, M. C., Su, L.-K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hedge, P., McKechnie, D., et al. (1991) · Science · doi:10.1126/science.1651562 · Cited by 2,331
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097
Mutations of Chromosome 5q21 Genes in FAP and Colorectal Cancer Patients
Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., Hedge, P., et al. (1991) · Science · doi:10.1126/science.1651563 · Cited by 1,891
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., BOOM, J. H. V., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 406
Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells
Pories, S. E., Hess, D. T., Swenson, K. K., Lotz, M. M., Moussa, R., Steele, G. D., Shibata, D., Rieger‐Christ, K., & Summerhayes, I. C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70435-4 · Cited by 34
Su, W., Sin, M., Darrow, A., & Sherman, L. S. (2003) · Glia · doi:10.1002/glia.10206 · Cited by 34
Shekhtman, A. G., Ghose, R., Wang, D., Cole, P. A., & Cowburn, D. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5126 · Cited by 34
Olszewska-Pazdrak, B., Townsend, C. M., & Hellmich, M. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400208200 · Cited by 33
Is there a genetic signature for liver metastasis in colorectal cancer?
Nadal, C. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i44.5832 · Cited by 33
Kaye, S. B., Aamdal, S., Jones, R. D., Freyer, G., Pujade-Lauraine, É., de Vries, E. G. E., Barriuso, J., Sandhu, S. K., Tan, D. S. W., Hartog, V., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.158 · Cited by 33
Sasaki, S., Ueda, M., Iguchi, T., Kaneko, M., Nakayama, H., Watanabe, T., Sakamoto, A., & Mimori, K. (2017) · Anticancer Research · doi:10.21873/anticanres.11603 · Cited by 33
Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 33
Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment
Heiska, L., Melikova, M., Zhao, F., Saotome, I., McClatchey, A. I., & Carpén, O. (2011) · Oncogene · doi:10.1038/onc.2011.207 · Cited by 32
The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility
Benes, C. H., Poulogiannis, G., Cantley, L. C., & Soltoff, S. P. (2011) · Oncogene · doi:10.1038/onc.2011.262 · Cited by 32
DDR1 promotes migration and invasion of breast cancer by modulating the Src-FAK signaling
Han, Q., Xiao, F., Ma, L., Zhou, J., Wang, L., Cheng, H., Zhu, J., Yao, F., Lyu, J., & Du, L. (2022) · Neoplasma · doi:10.4149/neo_2022_220316n289 · Cited by 32
EGFR and HER2 levels are frequently elevated in colon cancer cells
Li, S., Buchbinder, E. L., Wu, L., Bjorge, J. D., Fujita, D. J., & Zhu, S. (2014) · Discoveries Reports · doi:10.15190/drep.2014.1 · Cited by 32
Involvement of c‐Src in Carcinoma Cell Motility and Metastasis
Sakamoto, M., Takamura, M., Ino, Y., Miura, A., Genda, T., & Hirohashi, S. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01184.x · Cited by 32
Macrophage Stimulating Protein
Leonard, E. J., & Danilkovitch, A. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60786-1 · Cited by 32
Salotti, J., Dias, M. H., Koga, M. M., & Armelin, H. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072582 · Cited by 31
Hosoya, N., Qiao, Y., Hangaishi, A., Wang, L., Nannya, Y., Sanada, M., Kurokawa, M., Chiba, S., Hirai, H., & Ogawa, S. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20147 · Cited by 34
Konitsiotis, A. D., Roßmannek, L., Stanoev, A., Schmick, M., & Bastiaens, P. I. H. (2017) · Nature Communications · doi:10.1038/s41467-017-00116-3 · Cited by 30
SRC activates TAZ for intestinal tumorigenesis and regeneration
Byun, M. R., Hwang, J.-H., Kim, A. R., Kim, K. M., Park, J. I., Oh, H. T., Hwang, E. S., & Hong, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.003 · Cited by 30
Singh, M. M., Howard, A., Irwin, M. E., Gao, Y. H., Lü, X., Multani, A. S., & Chandra, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051611 · Cited by 30
Lauzier, A., Charbonneau, M., Harper, K., Jilaveanu-Pelmus, M., & Dubois, C. M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30305 · Cited by 31
Kunte, D. P., Wali, R. K., Koetsier, J. L., Hart, J. A. L., Kostjukova, M. N., Kilimnik, A. Y., Pyatkin, I. G., Strelnikova, S. R., & Roy, H. K. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.05.030 · Cited by 30
MOLECULAR PATHOGENESIS OF COLORECTAL CANCER
Hoops, T. C., & Traber, P. G. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70453-6 · Cited by 30
Allgayer, H., Leupold, J. H., & Patil, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.018 · Cited by 29
Noronha, G., Barrett, K., Cao, J., Dneprovskaia, E., Fine, R., Gong, X., Gritzen, C., Hood, J. D., Kang, X., Klebansky, B., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.035 · Cited by 29
Barlaam, B. C., Fennell, M., Germain, H., Green, T., Hennequin, L. F., Morgentin, R., Olivier, A., Plé, P. A., Vautier, M., & Costello, G. F. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.106 · Cited by 29
Potent Dipeptide Inhibitors of the pp60c-src SH2 Domain
Pacofsky, G. J., Lackey, K. E., Alligood, K. J., Berman, J., Charifson, P. S., Crosby, R. M., Dorsey, G. F., Feldman, P. L., Gilmer, T. M., Hummel, C. W., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970853a · Cited by 29
Sikalidis, A. K., & Varamini, B. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-010-9352-9 · Cited by 28
Chatterjee, T., Zhang, S., Posey, T. A., Jacob, J., Wu, L., Yu, W., Francisco, L. E., Liu, Q. J., & Carmon, K. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100261 · Cited by 28
Fujisaka, Y., Onozawa, Y., Kurata, T., Yasui, H., Goto, I., Yamazaki, K., Machida, N., Watanabe, J., Shimada, H., Shi, X., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9809-7 · Cited by 28
Lin, E. H., Hui, A. Y., Meens, J., Tremblay, E. A., Schaefer, E., & Elliott, B. E. (2003) · Experimental Cell Research · doi:10.1016/j.yexcr.2003.09.008 · Cited by 28
Brunton, V. G., Steele, G., Lewis, A. D., & Workman, P. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050760 · Cited by 28
The biology of colorectal carcinoma
Jessup, J. M., & Gallich, G. E. (1992) · Current Problems in Cancer · doi:10.1016/0147-0272(92)90049-t · Cited by 28
Activation of c-Src is Inversely Correlated with Biological Aggressiveness of Breast Carcinoma
Ito, Y., Kawakatsu, H., Takeda, T., Tani, N., Kawaguchi, N., Noguchi, S., Sakai, T., & Matsuura∥, N. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020860221099 · Cited by 27
Strickler, J. H., McCall, S. J., Nixon, A. B., Brady, J. C., Pang, H., Rushing, C. N., Cohn, A. L., Starodub, A., Arrowood, C., Haley, S. T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0042-9 · Cited by 27
Simoneau, M., Coulombe, G., Vandal, G., Vézina, A., & Rivard, N. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.09.011 · Cited by 27
Nourazarian, A., Najar, A. G., Farajnia, S., Khosroushahi, A. Y., Pashaei‐Asl, R., & Omidi, Y. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.9.4751 · Cited by 27
Stenzinger, A., Schreiner, D., Reiners-Koch, P.-S., Hofer, H. W., & Wimmer, M. A. (2009) · International review of cytology · doi:10.1016/s1937-6448(09)75006-3 · Cited by 28
Pongchairerk, U. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i37.5845 · Cited by 27
Boudný, V., & Nakano, S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600080 · Cited by 27
Welman, A., Cawthome, C., Ponce-Perez, L., Barraclough, J., Danson, S., Murray, S., Cummings, J., Allen, T. D., & Dive, C. (2006) · Neoplasia · doi:10.1593/neo.06475 · Cited by 26
Thorn, C. C., Freeman, T. C., Scott, N., Guillou, P. J., & Jayne, D. G. (2008) · Gut · doi:10.1136/gut.2008.157255 · Cited by 27
Rajala, R. V. S., Dehm, S. M., Bi, X., Bonham, K., & Sharma, R. K. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3066 · Cited by 26
Morrow, C. J., Ghattas, M. A., Smith, C. G., Bönisch, H., Bryce, R. A., Hickinson, D. M., Green, T. P., & Dive, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0694 · Cited by 26
Different metastatic potentials ofras- andsrc-transformed BALB/c 3T3 A31 variant cells
Tatsuka, M., Ota, T., Yamagishi, N., Kashihara, Y., Wada, M., Matsuda, N., Mitsui, H., Seiki, M., & Odashima, S. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199604)15:4 · Cited by 26
Evaluation of FAK and Src Expression in Human Benign and Malignant Thyroid Lesions
Michailidi, C., Giaginis, C., Stolakis, V., Alexandrou, P. T., Klijanienko, J., Delladetsima, I. K., Chatzizacharias, N., Tsourouflis, G. S., & Theocharis, S. E. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9269-3 · Cited by 25
New Structural Perspectives in G Protein-Coupled Receptor-Mediated Src Family Kinase Activation
Berndt, S., & Liebscher, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126489 · Cited by 25
Activation of β-catenin–TCF-mediated transcription by non-receptor tyrosine kinase v-Src
Haraguchi, K., Nishida, A., Ishidate, T., & Akiyama, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.021 · Cited by 25
Lee, H.-J., Kim, E., Jee, B., Hahn, J.-H., Han, K., Jung, K. C., Park, S. H., & Lee, H. (2002) · Experimental & Molecular Medicine · doi:10.1038/emm.2002.26 · Cited by 24
Novel Protein Kinase Inhibitors: SMART Drug Design Technology
Sawyer, T. K., Bohacek, R. S., Metcalf, C. A., Shakespeare, W. C., Wang, Y., Sundaramoorthi, R., Keenan, T. P., Narula, S. S., Weigele, M., & Dalgarno, D. C. (2003) · BioTechniques · doi:10.2144/sawyerjun03revised · Cited by 24
Field defects in progression to adenocarcinoma of the colon and esophagus
Bernstein, C., Bernstein, H., Payne, C. M., & Garewal, H. S. (2000) · Electronic Journal of Biotechnology · doi:10.2225/vol3-issue3-fulltext-1 · Cited by 24
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
Hikita, T., Oneyama, C., & Okada, M. (2010) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01439.x · Cited by 21
Nourazarian, A., Pashaei‐Asl, R., Omidi, Y., & Najar, A. G. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.5.2235 · Cited by 22
Recent advances in the discovery of Src kinase inhibitors
Parang, K., & Sun, G. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.9.1183 · Cited by 22
Atatreh, N., Stojkoski, C., Smith, P., Booker, G. W., Dive, C., Frenkel, A. D., Freeman, S., & Bryce, R. A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.115 · Cited by 22
Clinical significance of Src expression and activity in human neoplasia.
Chatzizacharias, N. A., Kouraklis, G. P., Giaginis, C., & Theocharis, S. E. (2012) · PubMed · doi:10.14670/hh-27.677 · Cited by 21
Kawczyk‐Krupka, A., Sieroń–Stołtny, K., Latos, W., Czuba, Z. P., Kwiatek, B., Potempa, M., Wasilewska, K., Król, W., & Stanek, A. (2015) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2015.09.003 · Cited by 21
von Wichert, G., Krndija, D., Schmid, H., von Wichert, G., Haerter, G., Adler, G., Seufferlein, T. T. W., & Sheetz, M. P. (2007) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2007.07.008 · Cited by 24
Somatic Mutations in CCK2R Alter Receptor Activity that Promote Oncogenic Phenotypes
Willard, M. D., Lajiness, M. E., Wulur, I. H., Feng, B., Swearingen, M. L., Uhlik, M. T., Kinzler, K. W., Velculescu, V. E., Sjöblom, T., Markowitz, S. D., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0483 · Cited by 21
Lu, X., Fairbairn, D. W., Bradshaw, W. S., O'Neill, K. L., Ewert, D. L., & Simmons, D. L. (1997) · Prostaglandins · doi:10.1016/s0090-6980(97)00125-1 · Cited by 21
Prognostic relevance of Src activation in stage II-III colon cancer
Martínez-Pérez, J., Lopez-Calderero, I., Saez, C., Benavent, M., Limon, M. L., Gonzalez-Exposito, R., Soldevilla, B., Riesco-Martínez, M. C., Salamanca, J., Carnero, A., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.025 · Cited by 20
SRC inhibition represents a potential therapeutic strategy in liposarcoma
Sievers, E., Trautmann, M., Kindler, D., Huss, S., Gruenewald, I., Dirksen, U., Renner, M., Mechtersheimer, G., Pédeutour, F., Åman, P., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29645 · Cited by 20
Theocharis, S. E., Klijanienko, J., Giaginis, C., Alexandrou, P. T., Patsouris, E., & Sastre‐Garau, X. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1215-1 · Cited by 20
Nacif-Pimenta, R., Orfano, A. S., Mosley, I. A., Karinshak, S. E., Ishida, K., Mann, V. H., Coelho, P. M. Z., da Costa, J. M. C., Hsieh, M. H., Brindley, P. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46917-y · Cited by 20
Crosstalk between Activated and Inactivated c-Src in Hepatocellular Carcinoma
Chen, M., Chai, C., Yeh, K., Wang, S., Tsai, C.-J., Yeh, Y., & Yang, S. (2011) · Disease Markers · doi:10.1155/2011/946295 · Cited by 20
Hermida‐Prado, F., Villaronga, M. Á., Granda‐Díaz, R., Del-Río-Ibisate, N., Santos, L. M., Hermosilla, M. A., Oro, P., Allonca, E., Agorreta, J., Garmendia, I., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081157 · Cited by 19
Nelson, L. J., Wright, H. J., Dinh, N. B., Nguyen, K. D., Razorenova, O. V., & Heinemann, F. S. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.10.017 · Cited by 19
Jia, J., Starodub, A., Cushman, I., Liu, Y., Marshall, D. J., Hurwitz, H. I., & Nixon, A. B. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835d29fd · Cited by 19
Mizenina, O. A., & Moasser, M. M. (2004) · Cell Cycle · doi:10.4161/cc.3.6.899 · Cited by 19
Cheng, S., Kok, S., Lee, J., Kuo, M. Y., Cheng, S.-L., Huang, Y., Chen, H., Chang, H., & Chiang, C. (2011) · Head & Neck · doi:10.1002/hed.21923 · Cited by 19
Fu, Y., Yang, G., Xue, P., Guo, L., Yin, Y., Ye, Z., Peng, S., Qin, Y., Duan, Q., & Zhu, F. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0062-5 · Cited by 19
Su, Y., Zhu, K., Wang, J., Liu, B., Chang, Y., Chang, D., & You, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117369 · Cited by 20
Hermida-Prado, F., Granda-Díaz, R., Del-Río-Ibisate, N., Villaronga, M., Allonca, E., Garmendia, I., Montuenga, L., Rodríguez, R., Vallina, A., Álvarez-Marcos, C., et al. (2019) · Cancers · doi:10.3390/cancers11111644 · Cited by 12
Kopetz, S., Morris, V. K., Parikh, N. U., Overman, M. J., Jiang, Z.-Q., Maru, D. M., Elvin, P., & Gallick, G. E. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-660 · Cited by 18
Self-citationPoon, C. L. C., Brumby, A. M., & Richardson, H. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061585 · Cited by 19
Kaulfuß, S., Seemann, H., Kampe, R., Meyer, J., Dressel, R., König, B., Scharf, J., & Burfeind, P. (2013) · Oncotarget · doi:10.18632/oncotarget.1085 · Cited by 18
c-Src dependency of NSAID-induced effects on NF- B-mediated apoptosis in colorectal cancer cells
Brady, R. R. W., Loveridge, C. J., Dunlop, M. G., & Stark, L. A. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr077 · Cited by 18
Kline, C. L. B., & Irby, R. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0648-3 · Cited by 17
Wang, M.-C., Lee, Y.-H., & Liao, P. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8352-0 · Cited by 17
Expression of c-Src and phospho-Src in epithelial ovarian carcinoma
Huang, Y.-W., Chen, C., Xu, M.-M., Li, J.-D., Xiao, J., & Zhu, X. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1550-1 · Cited by 17
Maślikowski, B. M., Néel, B., Wu, Y., Wang, L., Rodrigues, N., Gillet, G., & Bédard, P. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-41 · Cited by 17
Advani, G., Lim, Y. C., Catimel, B., Lio, D. S. S., Ng, N. L. Y., Chüeh, A. C., Tran, M. X., Anasir, M. I., Verkade, H. M., Zhu, H., et al. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0186-x · Cited by 16
AGO2 phosphorylation by c-Src kinase promotes tumorigenesis
Liu, T.-Q., Zhang, H., Fang, J.-Y., Yang, Z., Chen, R., Wang, Y.-L., Zhao, X., Ge, S., Yu, J.-X., & Huang, J. (2020) · Neoplasia · doi:10.1016/j.neo.2019.12.004 · Cited by 16
McKinley, E. T., Liu, H., McDonald, W. H., Luo, W., Zhao, P., Coffey, R. J., Hanks, S. K., & Manning, H. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080207 · Cited by 15
Lotz, M. M., Wang, H. H.-F., Cance, W. G., Matthews, J. B., & Pories, S. E. (2003) · Journal of Surgical Research · doi:10.1016/s0022-4804(02)00100-2 · Cited by 15
Zavieh, S. E., & Safari, F. (2022) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-022-01066-4 · Cited by 14
4-Hydroxynonenal activates Src through a non-canonical pathway that involves EGFR/PTP1B
Zhang, H.-Q., & Forman, H. (2015) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2015.08.025 · Cited by 13
Yao, Y., Bian, Y., Dong, M., Wang, Y., Lv, J., Chen, L., Wang, H., Mao, J., Dong, J., & Ye, M. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00546 · Cited by 14
Suppression of anoikis by v‐Src but not by activated c‐H‐Ras in human gallbladder epithelial cells
Hisano, C., Tanaka, R., Fujishima, H., Ariyama, H., Tsuchiya, T., Tatsumoto, T., Mitsugi, K., Nakamura, M., & Nakano, S. (2003) · Cell Biology International · doi:10.1016/s1065-6995(03)00032-5 · Cited by 14
Lin, P., Yang, Y.-F., Tyan, Y., Hsiao, E. S. L., Chu, P., Lee, C., Lee, J., Chen, Y. A., & Liao, P.-C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158844 · Cited by 13
Development of novel benzotriazines for drug discovery
Palanki, M. S. S., Cao, J., Chow, C. P., Dneprovskaia, E., Mak, C. C., McPherson, A. K., Pathak, V. P., Renick, J., Söll, R., Zeng, B., et al. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460440802580536 · Cited by 13
Kakarala, K. K., & Jamil, K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1891140 · Cited by 13
Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy
Sawyer, T. K. (2007) · Topics in medicinal chemistry · doi:10.1007/7355_2006_010 · Cited by 13
Bertrand, V., Couturier-Turpin, M.-H., Louvel, A., Panis, Y. H., & Couturier, D. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00194-0 · Cited by 13
Intestinal cell growth control: Role of Src tyrosine kinases
Cartwright, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70443-3 · Cited by 13
Haier, J., Gallick, G. E., & Nicolson, G. L. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01051.x · Cited by 13
Self-citationKollmorgen, G., Bossenmaier, B., Niederfellner, G. J., Häring, H., & Lammers, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053050 · Cited by 13
Padhan, N., Nordling, T. E. M., Sundström, M., Åkerud, P., Birgisson, H., Nygren, P., Nelander, S., & Claesson, L. (2016) · BMC Cancer · doi:10.1186/s12885-016-2725-z · Cited by 12
Troiani, T., Martinelli, E., Morgillo, F., Capasso, A., Nappi, A. G., Sforza, V., & Ciardiello, F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012462462 · Cited by 12
Src activity alters α3 integrin expression in colon tumor cells
Kline, C. L. B., Olson, T. L., & Irby, R. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9215-x · Cited by 12
Metadata
- Authors
- Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Talamonti, M S
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 53-60
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC329994
- OpenAlex
- W2030565228
- Cited by
- 399
- References
- 45
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 11 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 14 · 2016: 8 · 2015: 13 · 2014: 11 · 2013: 17 · 2012: 24
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca053167-06)
- National Cancer Institute (CA09599, CA53167, T32CA009599)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, tyrosine kinase activity, colorectal cancer, tumor progression, colonic polyps, liver metastasis, synchronous primary tumors, oncogene activation
- MeSH terms
- Adenocarcinoma, Adenoma, Antigen-Antibody Complex, Colonic Neoplasms, Colonic Polyps, Humans, Intestinal Mucosa, Liver Neoplasms, Neoplasm Metastasis, Neoplasm Staging, Phosphopyruvate Hydratase, Phosphorylation, Protein Kinases, Protein-Tyrosine Kinases, Rectal Neoplasms, Reference Values, Immunoblotting, Proto-Oncogene Proteins pp60(c-src)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
